Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Pathogens

Persons Infected with Novel Coronavirus May be ‘Symptom-Free’ for 5 Days

Pooled analysis of confirmed cases used to estimate length of incubation period of COVID-19

by Global Biodefense Staff
March 9, 2020
We Must Protect the Frontline Warriors Against COVID-19 by Ensuring Health Care Workers Have Necessary PPE

This scanning electron microscope image shows SARS-CoV-2 —previously known as 2019-nCoV, the virus that causes COVID-19. Credit: NIAID-RML

Research published this week in the Annals of Internal Medicine suggests that persons infected with SARS-CoV-2, the newly-identified virus that causes coronavirus disease COVID-19, may be symptom-free for about 5 days on average, and should expect to experience symptoms within 12 days.

The findings support current recommendations by the US Centers for Disease Control and Prevention (CDC) to actively monitor patients for 14 days after an assumed exposure to SARS-CoV-2 and have important implications for informing control activities.

Researchers from Johns Hopkins Bloomberg School of Public Health conducted an analysis of news reports, public health reports, and press releases from 50 provinces, regions, and countries outside of Wuhan, China to estimate the length of the incubation period of COVID-19, the time from exposure to symptom onset. They found information on 181 confirmed cases with identifiable exposure and symptom onset windows.

Based on the available data, the researchers estimated the median incubation period of COVID-19 to be 5.1 days and 97.5 percent of those who develop symptoms appeared to do so within 11.5 days of infection. These estimates imply that, under conservative assumptions, 101 out of every 10,000 cases will develop symptoms after 14 days of active monitoring or quarantine, which supports current CDC recommendations.

The authors caution that given recent evidence of SARS-CoV-2 transmission by mildly symptomatic and asymptomatic individuals, time from exposure to onset of infectiousness (latent period) may be shorter than the estimated incubation period, with important implications for transmission dynamics.


This information is not intended as medical advice or clinician guidance. This content contains edited excerpts to bring attention to the work of the researchers and study authors. Please support their efforts and click through for the full context.

Tags: CoronavirusCOVID-19Editor PickMagazine Edition 11 March 2020SARS-CoV-2

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC